SCHEMBL5144864

SCHEMBL5144864

FC(F)Oc1ccc(C2CCC2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD1 P21728 1/20 0.43
IDO1 P14902 1/20 0.42
ALDH1A1 P00352 4/20 0.41
KMT2A Q03164 3/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
TSHR P16473 1/20 0.41
MDM2 Q00987 1/20 0.41
SLC6A4 P31645 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
ESR2 Q92731 1/20 0.39
KCNH2 Q12809 1/20 0.38
HRH3 Q9Y5N1 1/20 0.38
HAO1 Q9UJM8 1/20 0.38
MEN1 O00255 1/20 0.38
LMNA P02545 1/20 0.38
HSP90AA1 P07900 1/20 0.38
PKM P14618 1/20 0.38
HPGD P15428 1/20 0.38
HTT P42858 1/20 0.38
CCR6 P51684 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5147786 0.96 ALDH1A1 (0.44) DRD1IDO1ALDH1A1KMT2AL3MBTL1
SCHEMBL5144846 0.94 KCNH2 (0.44) IDO1ALDH1A1KMT2ATSHRMDM2
SCHEMBL5146469 0.92 IDO1 (0.47) DRD1IDO1ALDH1A1KMT2ATSHR
SCHEMBL8766989 0.85 IDO1 (0.42) IDO1ALDH1A1KMT2AL3MBTL1TSHR
SCHEMBL4063657 0.85 IDO1 (0.41) DRD1IDO1ALDH1A1KMT2AL3MBTL1
SCHEMBL8452616 0.85 NPC1 (0.46) IDO1ALDH1A1KMT2ASLC6A4MEN1
SCHEMBL14924284 0.83 ESR2 (0.52) DRD1IDO1ALDH1A1KMT2AL3MBTL1
SCHEMBL13906289 0.80 IDO1 (0.41) DRD1IDO1ALDH1A1KMT2ATSHR
SCHEMBL13906280 0.80 IDO1 (0.41) DRD1IDO1ALDH1A1KMT2AL3MBTL1
SCHEMBL13906463 0.80 IDO1 (0.41) DRD1IDO1ALDH1A1KMT2ATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070299072-A1 KV1.5 POTASSIUM CHANNEL INHIBITORS WYETH (US) 2007-12-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070299072-A1 KV1.5 POTASSIUM CHANNEL INHIBITORS KCNA5, KCNH1, KCNK5 DRD1 1811/4885IDO1 2069/4885ALDH1A1 888/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.